Analysts Offer Predictions for MediWound FY2029 Earnings

MediWound Ltd. (NASDAQ:MDWD - Free Report) - HC Wainwright issued their FY2029 earnings estimates for MediWound in a note issued to investors on Thursday, March 20th. HC Wainwright analyst S. Ramakanth anticipates that the biopharmaceutical company will post earnings of $2.45 per share for the year. HC Wainwright has a "Buy" rating and a $25.00 price target on the stock. The consensus estimate for MediWound's current full-year earnings is ($2.66) per share.

MediWound (NASDAQ:MDWD - Get Free Report) last released its quarterly earnings data on Wednesday, March 19th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, beating the consensus estimate of ($0.59) by $0.23. The company had revenue of $5.84 million for the quarter, compared to analyst estimates of $5.79 million. MediWound had a negative return on equity of 82.17% and a negative net margin of 142.29%. During the same period in the prior year, the company posted ($0.19) EPS.

Other equities research analysts also recently issued research reports about the stock. StockNews.com upgraded shares of MediWound to a "sell" rating in a research note on Friday. Craig Hallum began coverage on shares of MediWound in a report on Friday, February 28th. They set a "buy" rating and a $39.00 price target for the company.

Remove Ads

MediWound Stock Up 1.3 %

NASDAQ:MDWD traded up $0.21 during trading hours on Friday, reaching $16.66. The company had a trading volume of 82,273 shares, compared to its average volume of 90,003. The stock has a 50-day moving average of $18.13 and a two-hundred day moving average of $17.59. MediWound has a one year low of $12.78 and a one year high of $24.00. The firm has a market capitalization of $179.81 million, a PE ratio of -5.74 and a beta of 0.82.

Institutional Trading of MediWound

Several large investors have recently made changes to their positions in the business. State Street Corp raised its holdings in shares of MediWound by 219.6% in the third quarter. State Street Corp now owns 66,258 shares of the biopharmaceutical company's stock valued at $1,197,000 after buying an additional 45,529 shares during the last quarter. Barclays PLC increased its position in MediWound by 311.3% in the 3rd quarter. Barclays PLC now owns 11,163 shares of the biopharmaceutical company's stock valued at $202,000 after acquiring an additional 8,449 shares in the last quarter. Rhumbline Advisers raised its stake in shares of MediWound by 7.3% in the fourth quarter. Rhumbline Advisers now owns 10,835 shares of the biopharmaceutical company's stock worth $193,000 after acquiring an additional 739 shares during the last quarter. Point72 Asset Management L.P. acquired a new position in shares of MediWound during the third quarter worth approximately $212,000. Finally, Essex Investment Management Co. LLC grew its stake in shares of MediWound by 30.7% during the fourth quarter. Essex Investment Management Co. LLC now owns 148,949 shares of the biopharmaceutical company's stock valued at $2,651,000 after purchasing an additional 35,012 shares during the last quarter. Institutional investors own 46.83% of the company's stock.

About MediWound

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.